Overview
Avastin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat lung, colorectal, breast, and several other cancers. Avastin is sometimes prescribed off-label to treat ovarian…

Overview

Avmapki Fakzynja Co-Pack is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with recurrent low-grade serous ovarian cancer (LGSOC) that has a mutation (change) in the KRAS gene…

Overview
Elahere is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary…

Overview

Keytruda is approved by the U.S. Food and Drug Administration (FDA) for use in combination with paclitaxel, with or without bevacizumab, to treat adults with platinum-resistant epithelial ovarian, fallopian tube…

Overview

Lifyorli is approved by the U.S. Food and Drug Administration (FDA) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have…

Overview
Lynparza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat deleterious germline or somatic BRCA-mutated advanced ovarian cancer who are in complete or partial response to…

Overview
Rozlytrek is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat cancerous tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known resistance…

Overview
Rubraca is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial…

Overview
Vitrakvi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance…

Overview
Zejula is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of adults with advanced or recurrent epithelial ovarian cancer who are in a complete or partial…